Trial record 26 of 153 for:    Open Studies | NIA

The Genetic Characterization of Dementia

This study is currently recruiting participants.
Verified September 2012 by National Institutes of Health Clinical Center (CC)
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) )
ClinicalTrials.gov Identifier:
NCT01867359
First received: May 29, 2013
Last updated: March 14, 2014
Last verified: September 2012
  Purpose

Background:

- Researchers are interested in learning more about dementia and its causes. They want to look at the genetic basis of dementia. Identifying genetic aspects of dementia may help provide better tests and treatments for it. It may also show rare gene variants that can cause or alter a person's risks for developing dementia. This study will look at people who have dementia, their family members, and healthy volunteers.

Objectives:

- To study genetic influences on dementia.

Eligibility:

  • Individuals who have been diagnosed with dementia.
  • Family members of individuals who have been diagnosed with dementia.
  • Healthy volunteers at least 18 years of age.

Design:

  • Participants will be interviewed and answer questions about their medical history. They will also provide general information on the relatives' medical histories.
  • Participants will provide a blood sample for genetic testing.
  • Participants will remain on the study for up to 10 years. They will have regular visits to monitor their brain health and function.
  • Treatment will not be provided as part of this study.

Condition
Dementia

Study Type: Observational
Official Title: The Genetic Characterization of Dementia

Resource links provided by NLM:


Further study details as provided by National Institutes of Health Clinical Center (CC):

Primary Outcome Measures:
  • Ascertain individuals and families with a clinical diagnosis of dementia [ Time Frame: Ongoing ] [ Designated as safety issue: No ]
  • Identify and characterize genetic contributions to etiology by collecting blood samples for DNA and cell line preparation [ Time Frame: Ongoing ] [ Designated as safety issue: No ]

Estimated Enrollment: 300
Study Start Date: March 2003
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Detailed Description:

Dementia is a condition of declining mental abilities, especially memory. Dementia can occur at any age but becomes more frequent with age, with a prevalence of 5%-10% in people over 65 and 20% in people over 80. Dementia affects the rate of information processing, short term memory is affected before long term memory. It is difficult to diagnose between even the three most common types: Alzheimers disease, Lewy Body disease and multi infarct dementia.

Alzheimer's disease (AD) is a genetically complex and heterogeneous disorder. It is the most common form of dementia, accounting for about 50-70% of typical, late onset cases of dementia. To date, mutations in three genes (APP, PSEN1, PSEN2) have been described to cause familial earlyonset AD. In addition, a common polymorphism in the gene encoding apolipoprotein E (APOE) has been associated with the more common late-onset form of the disease. Genetic variability at the APOE locus is a major determinant of late onset Alzheimer s disease. 5 Recent estimates suggest that these four established genes account for less than 30% of the genetic variance in age of onset for AD and predict that numerous AD genes may exist.

Lewy Body Disease includes a range of disorders: Parkinson s Disease, Dementia with Lewy bodies, and Parkinson s dementia, among others. Dementia with Lewy bodies (DLB) accounts for 20% of all cases of dementia in old age. Clinically DLB is characterized by cognitive impairment, visual hallucinations, and parkinsonism. Lewy bodies are neuronal inclusions comprised of abnormally truncated and phosphorylated neurofilament proteins, alpha-synuclein, ubiquitin and associated enzymes. Mutations in the alpha synuclein gene were first discovered in 1996 in a family with autosomal dominant Lewy body parkinsonism. However, most lewy body parkinsonism is not due to a variant in the -synuclein gene. The importance of -synuclein is attributed to the finding of antibodies to -synuclein stain Lewy bodies in brains of all Lewy body disease cases. The ability to identify underlying genetic influences that result in different synuclein pathologies is key to understanding these disorders.

The first aim of this protocol is to collect families with a history of dementia in an attempt to clone the causative gene defect(s) via linkage and positional cloning. Our experience with the cloning of the Amyloid Precursor Protein mutations in Alzheimer s disease shows that this approach leads to a better understanding of the biochemical and physiological processes underlying the disease.

It is clear there are numerous forms of dementia where disease does not appear to be inherited in a Mendelian manner. Whilst these may be caused by environmental effects it is also reasonable to hypothesize that disease may be caused by complex genetic interactions. Furthermore, the susceptibility to environmental influence may be affected by genetic predisposition. As a second aim in this protocol, we will investigate the association between genetic polymorphisms and dementia. This will be performed by a candidate gene approach, assessing the contribution of genes already associated with familial forms of disease, likely candidates (for example involved in the cholinergic system, cell survival or Beta Amyloid processing) or genes within a genetic region previously linked to disease. Although significant association does not imply a causal relationship between the presence of the variant and disease, the pathophysiologic significance should be studied further. The inevitable problem of false positives within this type of analysis is a real one, which may be addressed by independent replications and tightly controlled experiments. Undeniably the analytical effort needed to differentiate positives from false positives is considerable, and as can be readily seen in Alzheimer s disease, the literature is scattered with positive associations and subsequent refutations. However, it is important that research groups continue to identify and replicate these studies.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria
  • INCLUSION CRITERIA:

Previous diagnosis of Dementia by neurologist, other medical care provider, or researcher accompanied by sufficient clinical and/or laboratory evidence

Clinical confirmation of Dementia by the investigator and his associates either by exam and/or review of medical records

Family member of diagnosed dementia patient

Healthy controls

EXCLUSION CRITERIA:

Individuals with any movement disorder secondary to a specific environmental exposure, birth injury, metabolic disorder, or brain infection such as encephalitis.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01867359

Contacts
Contact: Andrew Singleton, Ph.D. (301) 451-6079 singleta@mail.nih.gov

Locations
United States, Maryland
National Institute of Aging, Clinical Research Unit Recruiting
Baltimore, Maryland, United States, 21224
Sponsors and Collaborators
Investigators
Principal Investigator: Andrew Singleton, Ph.D. National Institute on Aging (NIA)
  More Information

No publications provided

Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute on Aging (NIA) )
ClinicalTrials.gov Identifier: NCT01867359     History of Changes
Other Study ID Numbers: 999903326, 03-AG-N326
Study First Received: May 29, 2013
Last Updated: March 14, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Alzheimer's
Lewy Body
Familial
Parkinsonism

Additional relevant MeSH terms:
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Delirium, Dementia, Amnestic, Cognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on April 21, 2014